Mainstream

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Day One Biopharmaceuticals outlines $140M–$150M 2025 OJEMDA revenue target as new patient scripts accelerate

Post ContentdawnRead More

You might also be interested in reading This Analyst Predicted Solana Sell-Off At $250, And Is Back With A New Prediction.

August 6, 2025
In Mainstream